ONO-4538 Phase I Study in Patients With Solid Tumor
Status:
Completed
Trial end date:
2020-04-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to investigate the safety, pharmacokinetics, pharmacology and
efficacy of ONO-4538 administered to Korean patients with advanced or recurrent solid tumors
who are refractory or intolerant to standard therapy or for whom no appropriate treatment is
available.